Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14301 - 14325 of 15393 in total
Investigational
CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
Investigational
Matched Description: … of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A ... CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor …
Experimental
Matched Iupac: … (4S,6R,9E,11R,12R)-11-{[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy}-4-[(4R) ... -2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.0^{4,6}]trideca-1(13),9-dien-2,7-diyn-12-yl 2-hydroxy-7 …
PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
Investigational
Matched Description: … PTI-801 represents a new class of drugs to treat pain. ... It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. …
Experimental
Matched Iupac: … 2-amino-8-hydroxy-9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one …
Experimental
Matched Iupac: … (4S)-1-phenyl-7-(pyridin-3-yl)heptan-4-yl (2S)-1-[2,2-difluoro-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine …
Experimental
Matched Iupac: … {[(2R,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-yl] …
Cinepazide has been used in trials studying the treatment of Ischemic Stroke.
Investigational
Matched Iupac: … (2E)-1-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl}-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one …
Matched Description: … Cinepazide has been used in trials studying the treatment of Ischemic Stroke. …
GDC-0152 has been used in trials studying the treatment of Solid Cancers.
Investigational
Matched Iupac: … (2S)-1-[(2S)-2-cyclohexyl-2-[(2S)-2-(methylamino)propanamido]acetyl]-N-(4-phenyl-1,2,3-thiadiazol-5-yl …
Matched Description: … GDC-0152 has been used in trials studying the treatment of Solid Cancers. …
GSK2256098 is under investigation in clinical trial NCT02523014 (Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas).
Investigational
Matched Iupac: … 2-[(5-chloro-2-{[3-methyl-1-(propan-2-yl)-1H-pyrazol-5-yl]amino}pyridin-4-yl)amino]-N-methoxybenzamide …
Matched Description: … in Treating Patients With Progressive Meningiomas). ... GSK2256098 is under investigation in clinical trial NCT02523014 (Vismodegib and FAK Inhibitor GSK2256098 …
Etofylline nicotinate, a theophylline derivative, is a drug that causes vasodilation and relaxation of smooth muscle.
Experimental
Matched Description: … Etofylline nicotinate, a theophylline derivative, is a drug that causes vasodilation and relaxation of …
Investigational
Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
Investigational
Matched Description: … Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials …
FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
Investigational
Matched Description: … FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma. …
Investigational
Matched Iupac: … (2S,3R,5S)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl (2S)-2-amino-3-methylbutanoate …
Investigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).
Investigational
Investigational
Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).
Investigational
Matched Description: … Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb). …
Sacituzumab tirumotecan is a recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to a topoisomerase I inhibitor.
Investigational
Matched Description: … a topoisomerase I inhibitor. ... Sacituzumab tirumotecan is a recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to …
Experimental
Matched Iupac: … 4-hydroxy-3-{[(3S)-2-oxo-3-{thieno[3,2-b]pyridine-2-sulfonamido}pyrrolidin-1-yl]methyl}benzene-1-carboximidamide …
Experimental
Matched Iupac: … 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexan-1-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine …
Experimental
Matched Iupac: … 3-{1-[3-(dimethylamino)propyl]-1H-indol-3-yl}-4-(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione …
Experimental
Matched Iupac: … lambda4-iron(4+) 2-[(E)-{[5-(2-carboxyethyl)-2-[(E)-[(2-oxidophenyl)methylidene]amino]phenyl]imino}methyl …
CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.
Investigational
Matched Iupac: … 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}-1H-pyrazol-4-yl)-2,3,6,7-tetrahydro-1H-purine …
Matched Description: … CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics …
Investigational
Matched Iupac: … (3R)-3-[(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)methyl]-4-hydroxybutyl (2S)-2-amino-3-methylbutanoate …
Displaying drugs 14301 - 14325 of 15393 in total